Transient adverse events associated with the use of dupilumab in a child with severe atopic dermatitis

Atopic dermatitis is a multifactorial genetically determined inflammatory skin disease characterized by itching, chronic recurrent course, age-related features of localization and morphology of lesions. In a situation where external therapy for moderate to severe atopic dermatitis does not have sufficient effect, patients are prescribed systemic therapy. Currently, the genetically engineered biological drug dupilumab is in the first place in the systemic therapy of atopic dermatitis. Dupilumab is an effective drug in the treatment of atopic dermatitis, but at the same time has a number of side effects. This article describes a clinical case of a patient with severe atopic dermatitis and polyvalent food allergy, who initiated therapy with dupilumab. Against the background of the treatment, the patient had a consistent development of several undesirable effects - conjunctivitis, herpes infection, eosinophilia.